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ment such as intravenous immunoglobulin in two pa-
tients, hydroxychloroquine and azathioprine in two
and intravenous cyclophosphamide in one patient.
Sepsis was observed in three cSLE patients. Two pa-
tients required intensive care and death was observed
in one patient.
Conclusion: Our study identified SJS and overlap SJS-
-TEN as rare manifestations of active cSLE associated
with severe multisystemic disease, with potentially
lethal outcome.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a rare multisys-
tem autoimmune disease more common in adults
(aSLE) with 10% to 20% of cases beginning in children
and adolescents1. Childhood-onset SLE (cSLE) is cha -
racterized by the involvement of various organs and
systems, such as mucocutaneous, which has been
repor ted in 50 to 85% at the time of diagnosis or du -
ring the course of the disease2,3.
Stevens-Johnson syndrome (SJS) and toxic epider-
mal necrolysis (TEN) are severe cutaneous adverse re-
actions with high morbidity and mortality, usually in-
duced by medications or infections4,5. They result in
acute onset of target lesions followed by detachment of
the epidermis and epithelia resulting in extensive areas
of denuded skin, necrosis and mucosal erosions, ge -
nerally with the presence of Nikolski's sign4-7. Both di -
seases are part of a single spectrum of severe epider-
molytic reactions, differing mainly by the extent of skin
detachment and type of cutaneous lesions.
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ABSTRACT
Objective: To assess Stevens-Johnson syndrome (SJS)
and toxic epidermal necrolysis (TEN) in a large popu-
lation of childhood-onset systemic lupus erythemato-
sus (cSLE) patients.
Methods: Multicenter study including 852 cSLE pa-
tients followed in Pediatric Rheumatology centers in
São Paulo, Brazil. SJS was defined as epidermal de-
tachment below 10% of body surface area (BSA), over-
lap SJS-TEN 10-30% and TEN greater than 30% of
BSA.
Results: SJS and TEN were observed in 5/852 (0.6%)
cSLE female patients, three patients were classified as
SJS and two patients were classified as overlap SJS-TEN;
TEN was not observed. The mean duration of SJS and
overlap SJS-TEN was 15 days (range 7-22) and antibio -
tics induced four cases. Regarding extra-cutaneous
manifestations, hepatomegaly was observed in two
cSLE patients, nephritis in two and neuropsychiatric
involvement and conjunctivitis were observed respecti -
vely in one patient. Hematological involvement in-
cluded lymphopenia in four, leucopenia in three and
thrombocytopenia in two patients. The mean SLEDAI-
-2K score was 14.8 (range 6-30). Laboratory analysis
showed low C3, C4 and/or CH50 in two patients and
the presence of anti-dsDNA autoantibody in two 
patients. One patient had lupus anticoagulant and 
another one had anticardiolipin IgG. All patients were
treated with steroids and four needed additional treat-
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The initial lesions are characterized by atypical tar-
gets and/or purpuric macules commonly in upper tor-
so, proximal limbs, and face, spreading to the trunk
and distal limbs. Palms and soles are often involved.
Mucosal membranes of the eyes, mouth, nose and
geni talia can initially appear, leading to an erosive and
hemorrhagic mucositis7,8.
Other clinical features such as fever, malaise and
upper respiratory tract symptoms and ocular inflam-
mation can precede the eruption by several days.
Necrosis can occur in the epithelia of the respiratory
tract, causing bronchial and tracheal obstruction and
ventilatory compromise; in gastrointestinal tract, lead-
ing to exuberant diarrhea; and in kidneys, causing hy-
poperfusion, acute tubular necrosis and acute kidney
injury. Mild elevation of liver enzymes is usual, al-
though significant hepatitis or hepatic impairment are
rare 4,7.
Of note, SJS and TEN can occur simultaneously
with SLE6,9,10 and particularly in cSLE patients11-14.
There are, however, no reports characterizing their
prevalence and describing SJS and TEN in a large
popu lation of cSLE patients.
meThODS
STUDy DeSIgN AND pATIeNTS
A retrospective multicenter cohort study was per-
formed including 1,017 consecutive cSLE patients fol-
lowed in ten Pediatric Rheumatology tertiary referral
centers in São Paulo state, Brazil. The charts were re-
vised from 2012-2014.  One hundred and sixty five
patients were excluded due to: incomplete medical
charts (n=96), undifferentiated connective tissue di -
sorder with 3 or fewer American College of Rheuma-
tology (ACR) criteria for SLE15 (n=43), isolated cuta-
neous lupus erythematosus (n=11), neonatal lupus
erythematosus (n=8), drug-induced lupus (n=5) and
other autoimmune diseases (n=2)16. All the remaining
852 cSLE patients fulfilled the ACR criteria for SLE15,
with disease onset before 18 years of age17 and current
age up to 25 years old. In all the participant centers the
Committee for Research Ethics approved the study.
An investigator meeting was held in the beginning
of the study in the city of São Paulo to define the pro-
tocol, including definitions of clinical, laboratory and
treatment parameters, disease activity, SJS and TEN
characteristics and outcomes (intensive care unit stay
and death). All investigators used the same specific
database. All patient’s medical charts were reviewed
according to this standardized protocol.
SJS was defined as epidermal detachment below
10% of body surface area (BSA) with purpuric macules
or flat typical targets, overlap SJS-TEN with detach-
ment of 10-30% of BSA with purpuric macules or flat
typical targets and TEN with detachment of greater
than 30% of BSA with or without purpuric macules or
flat typical targets, also known as spots4,7,8.
All cSLE patients with the suspicion of SJS, overlap
SJS-TEN or TEN were evaluated by a local dermatolo -
gist. 
DemOgRAphIC DATA, ClINICAl evAlUATION,
DISeASe ACTIvITy AND DRUg TheRApy
Demographic data analysis included: gender, age at
SJS/TEN onset, duration of cSLE before SJS/TEN in
months and duration of SJS/TEN in days. Descriptors
and definitions of SLE clinical manifestations were
based on SLE Disease Activity Index 2000 (SLEDAI-
-2K) score of disease activity18, and were evaluated at
the manifestation of SJS/TEN. Other SJS/TEN characte -
ristics included the identification of the triggering
agent, presence of blisters/vesicles and mucosal in-
volvement, percentage of body surface area with epi-
dermal detachment and extra-cutaneous involvement.
Other cumulative SLE clinical manifestations inclu ded
hepatomegaly [based on physical exam with liver edge
≥ 2 cm below the right costal margin or imaging (ul-
trasound or computer tomography when available)]
and splenomegaly [based on physical exam with pal-
pable spleen or imaging (ultrasound or computer to-
mography when available)]. Neuropsychiatric lupus
included 19 syndromes according to ACR classifica-
tion criteria19. 
Complement levels (CH50, C3 and C4) were as-
sessed by immunodiffusion, turbidimetric im-
munoassay or immunonephelometry. Anti-double-
-stranded DNA (anti-dsDNA) was assessed by indirect
immunofluorescence or Enzyme Linked Immuno Sor-
bent Assay (ELISA); anticardiolipin (aCL) IgG and IgM
autoantibodies by ELISA. All the autoantibodies pro-
file were carried out at each center. The cutoff values
from the kit manufacturer were used to define abnor-
mal. Lupus anticoagulant was detected according to
the guidelines of the International Society on Throm-
bosis and Hemostasis20.
Drug treatment data (prednisone, intravenous
methylprednisolone, chloroquine diphosphate, hy-
droxychloroquine sulfate, azathioprine, cyclosporine,
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hematological involvement, such as lymphopenia
<1,500/mm3 in four, leucopenia <4,000/mm3 in three,
and thrombocytopenia<100,000/mm3 in two cSLE pa-
tients.
The mean SLEDAI-2K score was 14.8 (range 6-30).
The laboratory tests analysis showed low C3, C4 and/or
CH50 in two patients and the presence of anti-dsDNA
antibodies in two patients. One patient had lupus an-
ticoagulant positive and another one had anticardio -
lipin IgG.
Therapy in cSLE patients with SJS and TEN com-
prised of steroid use either in intravenous methyl-
prednisolone or prednisone. Four patients needed 
additional treatment, such as intravenous immuno -
globulin in two patients, combined hydroxychloro-
quine and azathioprine in two and intravenous cy-
clophosphamide in one patient. Regarding outcome,
two patients required intensive care unit and death was
observed in one patient. 
DISCUSSION
Our multicenter study characterized SJS and overlap
micofenolate, intravenous cyclophosphamide, intra-
venous immunoglobulin) were also recorded. 
ReSUlTS
SJS and TEN were observed in 5/852 (0.6%) cSLE pa-
tients, all girls, with age ranging between 2 to 18 years
old. Three patients were classified as SJS and two pa-
tients were classified as overlap SJS-TEN; TEN was not
observed. In one patient these manifestations occurred
at SLE diagnosis and in four patients during the fol-
low-up. The mean duration of SJS and overlap SJS-TEN
was 15 days (range 7-22) and four cases were induced
by antibiotics. Demographical and clinical characteris-
tics as well as disease activity (SLEDAI-2K) of the five
cSLE patients were shown in Table I. Presence of au-
toantibodies, treatment and outcome were shown in
Table II.
All patients had blisters, vesicles and mucosal in-
volvement. Regarding extra-cutaneous manifestations,
sepsis was observed in three patients, hepatomegaly in
two, nephritis in two, conjunctivitis in two and neu-
ropsychiatric involvement in one. Four patients had
TABle I. DemOgRAphICAl, ClINICAl ChARACTeRISTICS AND DISeASe ACTIvITy Of The fIve SJS/TeN cSle
pATIeNTS
Variables Case 1 Case 2 Case 3 Case 4 Case 5
Age (years) / gender 11 / Female 18 / Female 2 / Female 13 / Female 10 / Female
Duration of cSLE before 0 43 2 48 11
SJS/TEN (months)
Duration of SJS/TEN (days) 14 7 22 20 17
Identification of the triggering Antibiotics No Antibiotics Antibiotics Antibiotics
agent
Blisters/vesicles and mucosal Yes Yes Yes Yes Yes
involvement 
Epidermal detachment, 5 20 11 Less than 10 Less than 10
% of body surface area
Extra-cutaneous involvement Conjunctivitis Sepsis Hepatomegaly Sepsis Conjunctivitis
Sepsis Nephritis Leucopenia Nephritis




SLEDAI-2K at SJS/TEN 10 15 13 6 30
*SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, cSLE: childhood-onset systemic lupus erythematosus, 
SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.
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cal criteria: the pattern of individual skin lesions, their
distribution and the maximum extent of epidermal de-
tachment7-9. Importantly, due to the large detachment
of the skin, TEN patients have higher mortality rates4,7.
The alternative diagnosis to SJS and TEN such as ery-
thema multiforme and drug induced lesions, pemphi-
gus, pemphigoid, acute graft versus host disease and
other immunobullous diseases as well as infectious
disea ses like Mycoplasma, Herpes virus and HIV must
be ruled out7.
In some cases, the diagnosis of lupus-induced TEN
and classical TEN is intriguing. In both cases the clas-
sical clinical and histopathological features will be pre-
sent, with epidermolytic reactions and skin detachment
due to inflammatory dermatoses with keratinocyte
apoptosis and the same molecular mediators in-
volved13.  Lupus-induced TEN tend to have a subacute
presentation of weeks with the absence of systemic in-
volvement and no history of drug ingestion, while clas-
sical TEN has an acute evolution within 3 to 4 days or
sometimes within hours, with a close drug-related
causality and negative immunoflorescence4,21. In con-
trast to SJS-TEN, cutaneous lupus demonstrates the
prototypic interface dermatitis with deposition of im-
munoglobulins (IgG, IgM and/or IgA, C3) in direct im-
munofluorescence13,22,23. 
In both manifestations, renal involvement is com-
mon. It is known that in cSLE renal disease has been
reported in almost two thirds of the patients and more
frequent than the adult population24, 25. Due to systemic
drug-induced hypersensitivity, SJS and TEN can also
SJS-TEN as rare manifestations in a large cSLE popu-
lation. The advantage of including a large cSLE popu-
lation selected in tertiary referral centers allowed a bet-
ter evaluation of these rare and potentially lethal
manifestations. The use of a standardized combined
database, with proper SJS, overlap SJS-TEN and TEN
definitions minimized possible bias. In addition, in two
large prospective European studies characterizing SJS
and TEN, association with SLE and other autoimmune
rheumatologic diseases was found in approximately 0.6
to 5% of all patients with these severe manifestations8,9.
We found five (0.6%) cSLE patients with SJS and over-
lap SJS-TEN in our cohort population, and one of them
was previously reported (patient 1)11. TEN seemed to
be rarer since we did not find any patient in our cohort
study.
However, the main limitation of this study was the
retrospective design and possible missing data. In addi -
tion, skin biopsies were not a routine procedure in all
participant Pediatric Rheumatology centers. Only one
patient had SJS features confirmed by autopsy (case 2).
However, all other patients had a close drug causality
and were evaluated by a local experient dermatologist.
These skin vesiculobullous diseases are severe and
life-threatening cutaneous adverse reactions mainly
caused by drugs, infections or sometimes, unidentified
causes7-9, 21. Antibiotics are the most frequent cause fol-
lowed by anti-inflammatories and analgesics, as obser -
ved herein4. Other organs are described to be involved
as we found in most cases.
Classification of SJS and TEN is based on three clini -
TABle II. SeROlOgICAl AND lABORATORIAl ChARACTeRISTICS, TReATmeNT AND OUTCOme Of The fIve
SJS/TeN cSle pATIeNTS
Variables Case 1 Case 2 Case 3 Case 4 Case 5
Low C3, C4 and/or CH50 Yes No No No Yes
Anti-dsDNA Yes Yes No No No
Antiphospholipid antibodies No LA ACL IgG No No
Use of steroids Prednisone Prednisone Prednisone 1mg/kg Prednisone Prednisone 1mg/kg
2mg/kg 1mg/kg Intravenous 0.8mg/kg Intravenous
methylprednisolone methylprednisolone
Other treatment for SJS/TEN IVIG Cyclophosphamide Hydroxychloroquine None Hydroxychloroquine
IVIG Azathioprine Azathioprine
ICU stay Yes Yes No No No
Death No Yes No No No
*SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, cSLE: childhood-onset systemic lupus erythematosus, Anti-dsDNA:
double-stranded DNA, LA: Lupus anticoagulant, ACL IgG: Anticardiolipin IgG, IVIG: Intravenous immunoglobulin, ICU: Intensive Care Unit
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